Physician profile

Sandy Lifan Chen

Ophthalmology · San Jose, CA

NPI 1285624213

$677.46

in general payments reported to CMS, 2019-2025

4 companies · $24.04 in 2025

The $24.04 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$24.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $291.39 2019-2022
Amgen INC. $258.66 2019-2021
Johnson & Johnson Surgical Vision, INC. $103.37 2019
Abbott Laboratories $24.04 2025 Alinity

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sandy Lifan Chen

$677.46

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $24.04 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).

https://glasscript.com/doctor/194451/sandy-lifan-chen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.